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ABSTRACT 
Prenatal diagnosis enables identification of severe disease in the fetus, and allows for planning and 
management of future pregnancies if an underlying genetic mechanism is identified. The studies 
included in this thesis have taken advantage of the dramatic progress in medical genetics, in order to 
develop and evaluate new procedures to diagnose genetic disorders in fetal life. A correct diagnosis is 
important not only for the management and counseling of the patient or couple, but may also have an 
impact on the extended family, as there may be undetected carriers.  
The incidence of stillbirth in Sweden, i.e. fetal death occurring at gestational week ≥22, has essentially 
remained constant since the 1980’s, and despite thorough investigation, many cases remain 
unexplained. In Paper I, clinical chromosome analysis results from 481 stillbirth cases were 
compiled, and a subgroup of 90 cases were analyzed using chromosomal microarray (CMA) to study 
the potential benefits of the method. The conventional analysis detected chromosomal aberrations in 
7.5% of the cases. CMA additionally identified two known syndromes, one disruption of a known 
disease gene, and 26 variants of unknown significance. Furthermore, CMA had a significantly higher 
success rate than cytogenetic analysis (100% vs. 80%, p<0.001). As CMA increased both the success 
rate and diagnosis rate, we concluded that it is a valuable tool in stillbirth investigation. In Paper II, 
DNA from 290 stillbirth cases was analyzed by massive parallel sequencing of 79 genes associated 
with heart disease. Sixty-two cases (21.4%) had putative pathogenic variants in genes associated with 
channelopathies (53%), cardiomyopathies (24%) or congenital heart defects (23%). Screening for 
pathogenic variants in genes associated with heart disease might be a valuable complement in cases 
where the conventional investigation does not reveal the underlying cause of fetal demise. 
Fetal tissue calcifications are occasionally noted during autopsy or ultrasound, but their biological 
importance is largely unexplored. In Paper III, a case-control study including 151 calcification cases 
and 302 matched controls was performed, to identify factors associated with calcifications. 
Chromosomal abnormalities, detected by conventional chromosome analysis or quantitative 
fluorescence-polymerase chain reaction, were significantly more common in cases compared with 
controls; 50% vs. 20% (p<0.001). When comparing cases and controls with chromosomal 
abnormalities, the cases had a significantly higher prevalence of malformations (96% vs. 77%, 
p=0.002). We concluded that fetal tissue calcifications are associated with chromosomal 
abnormalities, especially in combination with malformations.  
Non-invasive prenatal testing (NIPT) for fetal aneuploidy, based on sequencing analysis of cell-free 
fetal DNA in maternal plasma, has recently been made possible. Current methods require DNA 
amplification prior to sequencing, which inevitably leads to a bias because some DNA fragments 
amplify more efficiently than others. In Paper IV, an amplification-free NIPT protocol was evaluated 
on 31 samples, of which 15 had confirmed aneuploidies. All aneuploidies were correctly classified, 
except in one case where cytogenetic testing had confirmed the presence of both trisomy 18 and XXY, 
but NIPT failed to identify the extra X chromosome. Further analyses revealed that the fetus was 
mosaic, which probably explains why the extra X chromosome was missed. We concluded that the 
amplification-free protocol can potentially be used for NIPT, as it could distinguish aberrant samples 
from healthy controls. Compared to other NIPT protocols, it can be used on smaller quantities of input 
DNA, reduces GC bias and increases genome coverage.  
In Paper V, we aimed to gain an increased understanding of pregnant women’s awareness, attitudes, 
and preferences concerning prenatal testing with emphasis on NIPT, before its introduction into 
Swedish healthcare. In total, 1,003 pregnant women were recruited to fill in a questionnaire at nine 
maternity clinics located in different areas of Stockholm. The overwhelming majority of the women 
(91%) considered examinations aiming to detect fetal abnormalities to be good. Regarding NIPT, 60% 
stated that they had heard about the method previously, yet 74% would like to use the test if available. 
The main factor affecting the women’s decision to undergo prenatal chromosomal screening was 
worry about the baby’s health (83%), followed by the desire to have as much information as possible 
about their fetuses (55%).  
The results from the studies have provided support for the value of various genetic analysis methods 
in the field of prenatal diagnosis, as well as insights to the prevalence of genetic aberrations in fetuses. 
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Array-CGH Array-based comparative genomic hybridization 
bp Basepairs 
BrS Brugada syndrome 
CADD Combined annotation dependent depletion 
CI Confidence interval 
cfDNA Cell-free DNA 
cffDNA Cell-free fetal DNA 
CHD Congenital heart defect 
CMA Chromosomal microarray 
CNV Copy number variant 
CPM Confined placental mosaicism 
CPVT Catecholaminergic polymorphic ventricular tachycardia 
CVS Chorionic villus sampling 
DNA Deoxyribonucleic acid 
ExAC Exome Aggregation Consortium 
FCT First trimester combined test 
FoSTeS Fork-stalling and template switching 
HCM Hypertrophic cardiomyopathy 
kb Kilobases, thousands of basepairs 
LoF Loss-of-function 
LQTS Long QT syndrome 
Mb Megabases, millions of basepairs 
MMBIR Micro-homology mediated break induced repair 
MPS Massive parallel sequencing 
NAHR Non-allelic homologous recombination 
NHEJ Non-homologous end-joining 
NGS Next-generation sequencing 
NIPT Non-invasive prenatal testing 
NRC Normalized read count 
PCR Polymerase chain reaction 
PPV Positive predictive value 
QF-PCR Quantitative fluorescence-polymerase chain reaction 
RhD Rhesus D 
SIDS Sudden infant death syndrome 
SNP Single nucleotide polymorphism 
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1 INTRODUCTION 
Prenatal diagnosis enables detection of severe disease already present in the fetus. 
Information about the fetal health status is important for pregnancy management, for deciding 
whether to continue the pregnancy, and for the planning and management of possible 
complications associated with the delivery and caretaking of the child after birth. 
Additionally, in case of a genetic disorder, identification of the underlying genetic 
mechanism enables estimations of the recurrence risk in future pregnancies. This project has 
taken advantage of the dramatic progress in medical genetics, in order to develop and 
evaluate new procedures to diagnose genetic disorders in fetal life. A correct diagnosis is 
important not only for the management and counseling of the patient or couple, but in the 
case of a genetic disease it may also have an impact on the extended family, as there may be 
undetected carriers also at risk of having affected offspring.  
1.1 EMBRYONIC AND FETAL DEVELOPMENT 
The human gestational period lasts for roughly 40 weeks, and is divided into three trimesters; 
each comprising three months. During this time a single cell, the zygote, will develop into a 
full-grown fetus. The gestational weeks are counted based on the first day of the last 
menstrual period, with fertilization taking place in the end of the second gestational week. 
The first eight weeks following fertilization are known as the embryonic period, which 
includes several developmental processes. The first embryonic cell divisions are called 
cleavages, as they result in no increase in the embryonal size. Cleavages occur until the 
embryo consists of a compact ball of equal cells; the morula. As the cells continue dividing, 
the compact morula will eventually develop into a hollow blastocyst. The blastocyst is 
composed of two distinct cell types; the embryoblasts, which constitute the inner cell mass, 
and the trophoblasts surrounding them. The inner cell mass will eventually develop into the 
fetus, whereas the trophoblasts will become the placenta. In the process of gastrulation, which 
occurs during the third embryonal week, the inner cell mass will evolve into three distinct 
germ layers; the ectoderm, the mesoderm and the endoderm. This is a crucial event as the 
layers are the first step towards organogenesis, i.e. formation of precursors to all organs in the 
body. Organogenesis lasts throughout the embryonic period, i.e. until gestational week 10. 
The fetal period, which begins in gestational week 11, is mainly devoted to the maturation of 
all organs, and fetal growth. By the time at which the fetal period is about to begin, the 
embryo is approximately 1 cm in size, and weighs around 8 grams. By term, the fetus will be 
50 cm in length and weigh around 3 kg. Most of the growth in length takes place during the 
second trimester, whereas most of the weight is put on in the third trimester1.  
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1.1.1 Stillbirth 
Pregnancy loss is very common; only around half of conceptuses (i.e. products of conception) 
will make it until term2. However, most pregnancy losses occur in early pregnancy. Stillbirth, 
on the other hand, is defined as ante- or intrapartal death occurring from 22 completed 
gestational weeks. It has an incidence of 3-4/1,000 live births in Sweden, according to the 
Swedish Medical Birth Register (data from 2014)3, and can be caused by several factors, such 
as genetic mechanisms, maternal conditions, infections, placental insufficiency and placental 
abruption4,5. The proportion of cases that is due to genetic causes is still uncertain and 
depends on how the cases are categorized. In many studies, all malformations are considered 
to have a genetic background, and the stillbirths are hence classified as such, even if the 
underlying genetic cause is not identified. Using traditional chromosome analysis, 6-17% of 
the stillborn has a proven chromosomal abnormality6. 
All cases of stillbirth in the Stockholm County pass a thorough investigation, with the aim of 
identifying the underlying cause of fetal demise. The investigation includes physical 
examination and autopsy, infectious disease testing and chromosome analysis. Yet, after a 
full investigation, up to 20% are classified as unexplained7. The incidence of stillbirth in 
Sweden has essentially remained constant since the 1980’s3, and better knowledge of the 
underlying mechanisms is needed in order to achieve a reduction in the stillbirth rate. The 
development of chromosome analysis methods with a higher resolution than the traditional 
methods has drawn attention towards the clinical impact of submicroscopic chromosomal 
abnormalities, which previously have remained undetected. Additionally, studies suggest that 
a proportion of stillbirth cases are due to heart disease, mainly channelopathies, i.e. defects in 
cardiac ion channels leading to a disrupted action potential propagation and thereby causing 
development of arrhythmias8. It is of importance to determine the underlying cause, as a 
history of stillbirth is associated with an increased recurrence risk in future pregnancies9,10. 
Furthermore, better understanding of the reason why the pregnancy ended in a stillbirth can 
help the parents deal with the loss.  
1.1.2 Fetal tissue calcifications 
During fetal autopsy, and more rarely also at ultrasound analysis, fetal tissue calcifications 
are occasionally noted, mainly in the liver. Most of them are so-called microcalcifications 
that can only be visualized using microscopy, but if sufficiently large, they can be detected 
with the naked eye. As opposed to many other morphological features, which in many cases 
are damaged in the autolysis process, fetal liver calcifications can be visualized on 
histological sections regardless of the degree of autolysis11. Although the occurrence of 
calcifications has been known for a long time, their biological importance is largely 
unexplored. Previous studies have indicated associations with infection12-14, circulatory 
compromise11,15, malformations or chromosomal abnormalities11,12,16-18. 
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1.2 EARLY FORMS OF PRENATAL DIAGNOSIS 
The development of the unborn child has fascinated people for many centuries. The oldest 
known documented representation of a human embryo dates back to 3,000-2,500 BC and 
pictures embryos at approximately 9 gestational weeks, discovered in a temple dedicated to a 
fertility goddess in Malta19. However, it would take another 5,000 years until a fetus could be 
visualized in utero. In 1923, the benefit of using x-rays to study fetuses was presented. Using 
this method, fetal position, bone structure and gestational age could be assessed20, but over 
the next decades it became increasingly evident that x-rays had harmful effects on the fetus. 
By 1975, strong evidence showed that x-rays could lead to miscarriage, fetal malformation, 
increased risk for childhood cancer and changes in the sex ratio21,22. During the same period 
of time, ultrasound imaging emerged as an alternative to x-ray, and quickly became the 
method of choice23, as it still is today. A beam of ultrasound is used for scanning, and a 
computer analyzes the pattern of the returning echoes. Because tissues of different densities 
reflect sound differently, bodily structures of the fetus can be visualized. 
In parallel with the development of fetal visualization techniques, methods for fetal genetic 
testing began to evolve. The first step towards prenatal genetic diagnosis was made by the 
Canadians Barr and Bertram in 1948. They discovered that cells derived from females of 
many species, including humans, contained a condensed body in the nuclear periphery24. 
They hypothesized that this body, which they called the sex chromatin but subsequently 
became known as the Barr body, could be used for sex determination if a sufficient amount of 
cells were studied. Methods to collect fetal cells were already available as amniocentesis, i.e. 
withdrawal of amniotic fluid, had been developed to treat fluid excess (polyhydramnios)25. 
By combining these two techniques, the fetal sex could be determined with high accuracy, 
which was valuable information in cases where a sex-linked disease, such as hemophilia, was 
present in a family26. Approximately ten years after the discovery of the Barr body, the 
number of human chromosomes was established, and shortly thereafter it was discovered that 
some congenital syndromes, e.g. Down syndrome and Klinefelter syndrome, are due to an 
abnormal number of chromosomes27. In the early 1970’s, a technical innovation – 
chromosome banding – took chromosome analysis to a new level. It enabled identification of 
specific chromosomes, as well as structural chromosomal changes28.  
1.3 GENETIC ABERRATIONS 
The human genome is almost two meters in length. To fit the genome in each cell nucleus, 
which in a typical cell is 6µm in diameter, it is tightly packed into chromosomes. Each 
chromosome contains a single molecule of deoxyribonucleic acid (DNA), which is packed in 
multiple levels of condensation by histones and other proteins (Figure 1). 
The DNA itself is built by nucleotides, which consists of three components; a phosphate 
group, a deoxyribose sugar group, and a nitrogen base. The phosphate and sugar together 
form the backbone of the DNA molecule, whereas there are four different types of bases; 
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adenine (A), thymine (T), cytosine (C), and guanine (G). All genetic information is contained 
in the sequence of the bases. The DNA is a double-stranded molecule, i.e. it consists of two 
strands of nucleotides that are held together by hydrogen bonding between the bases (A with 
T or C with G). The complementary structure of DNA ensures reliable replication of the 
genome, which thus can be transmitted to the next generation. However, errors do occur, and 
can range from a change of a single nucleotide to gain or loss of whole chromosomes. Hence, 
genetic aberrations can result in a wide variety of phenotypes, and each type of aberration 
requires its own special set of techniques to identify them.  
Figure 1. The hierarchical structure of DNA packed in a chromosome. 
1.3.1 Numerical chromosomal abnormalities 
The haploid human genome contains 23 chromosomes. The haploid chromosome set is found 
in the gametes, i.e. oocytes (“eggs”) or sperm cells, which are produced by meiotic cell 
division. Following fertilization, one oocyte and one sperm together form a zygote, i.e. the 
first cell of a new individual. The zygote is consequently diploid; it contains 46 
chromosomes. By mitotic cell division, the zygote will transmit the diploid chromosome set 
to its daughter cells. The 46 chromosomes include 22 pairs of autosomes, named 1-22, and 
one pair of sex chromosomes, which is XX in females or XY in males. One chromosome in 
each pair derives from the oocyte whereas the other derives from the sperm cell. The total 
number of chromosomes as well as the sex chromosomes in diploid cells is referred to as the 
karyotype of an individual. A normal karyotype in a female and a male is hence 46,XX and 
46,XY, respectively.  
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As indicated by its name, a numerical chromosomal abnormality refers to an abnormality 
where the number of chromosomes differs from the normal 46. There are two main types of 
numerical abnormalities; aneuploidy and polyploidy. Aneuploidy is a phenomenon which 
results from gain or loss of single whole chromosomes. A gain of a chromosome will lead to 
that there are three homologs instead of two in each cell, i.e. a trisomy. Conversely, loss of a 
chromosome results in a monosomy. Aneuploidies usually originate from an error known as 
non-disjunction occurring in the meiotic cell division, or during mitosis in the early embryo. 
The most common aneuploidy in early embryos and fetuses involve chromosome 16, 
followed by the acrocentric autosomes (which are chromosomes 13, 14, 15, 21, and 22)29,30. 
However, most of these will not result in a viable offspring. The most common aneuploidies 
observed in the late fetus (≤20 weeks) as well as in born children are trisomy 21 (Down 
syndrome), trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome) as well as 
aneuploidies involving the sex chromosomes31. 
A polyploidy infers that one or more complete sets of chromosomes are gained in a cell. Gain 
of one extra set results in a triploidy, i.e. 69 chromosomes, and a tetraploidy consequently 
means that there are 92 chromosomes in each cell. The formation of polyploidy can occur by 
fertilization of the oocyte by multiple sperm, or that the oocyte contained a diploid set of 
chromosomes prior to fertilization32. Polyploidy is usually not compatible with life in human, 
but is not uncommon in the early embryo or fetus, occurring in 1-3% of conceptuses32,33. In 
addition to aneuploidy and polyploidy there is mixoploidy, which is a state in where multiple 
cell lines, which can differ in regard to their chromosomal setup, are present in the same 
individual. If the cell lines are derived from the same zygote, it is known as mosaicism, 
whereas if they are derived from different zygotes it is known as chimerism. 
In the context of prenatal diagnosis, numerical chromosomal abnormalities constitute the 
group of aberrations that has traditionally been in focus. The risk of numerical aberrations 
increases with maternal age, although the mechanism behind this increase is not fully 
understood. 
1.3.2 Structural chromosomal abnormalities 
Structural chromosomal abnormalities are, as the name implies, changes in the chromosomal 
structure. There are different types of structural variants, including translocations, inversions, 
deletions and duplications, as well as complex rearrangements. Translocations commonly 
occur when two or more chromosomes break and the loose ends are joined together in the 
wrong order, but they can also arise from mechanisms associated with replication. A special 
type is the Robertsonian translocation, which is caused by fusion of the long arms of two 
acrocentric chromosomes. Translocations can be balanced, meaning that although in a 
rearranged order, all genetic information is present in the correct amount. Unless the 
breakpoints are located in, or in close proximity to, a disease causing gene, balanced 
translocations usually do not give rise to a clinical phenotype in the carrier, but can cause 
problems in meiosis resulting in unbalanced gametes. As a result, balanced translocations are 
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a well-known cause of infertility and repeated miscarriages34,35, but can also result in 
offspring with developmental delay and/or congenital malformations due to the fact that the 
translocations can be inherited in an unbalanced manner. An inversion, in contrast to a 
translocation, involves only one chromosome. The common mechanism of formation is 
chromosome breakage at two sites, whereupon the middle part is rotated 180° before 
reintegration into the same chromosome. As with translocations, an inversion usually does 
not cause symptoms in the carrier, but can give rise to unbalanced gametes. 
Deletions and duplications, i.e. loss or gain of chromosome segments, are also known as copy 
number variants (CNVs). CNVs can arise from several mechanisms, such as non-allelic 
homologous recombination (NAHR), non-homologous end joining (NHEJ), micro-homology 
mediated break induced repair (MMBIR)/Fork-stalling and template switching (FoSTeS)36, 
or of inheritance of a translocation or inversion in an unbalanced manner. Depending on their 
location in the genome and the copy number status (loss or gain), CNVs can influence gene 
expression and phenotypic variation, including development of disease. However, a lot of 
CNVs are benign normal variants that are found in the general population. 
Because of its limited resolution, traditional chromosome analysis only can only detect CNVs 
if they are very large, minimum 5-10 megabases (Mb, millions of basepairs). Therefore, until 
recently, the impact of smaller CNVs has been largely unknown in the context of fetal 
development. However, submicroscopic CNVs are today recognized as a major cause of 
genetic disorders postnatally, estimated to cause approximately 14-17% of intellectual 
disability and/or multiple congenital anomalies37,38. 
1.3.3 Nucleotide sequence variants 
The smallest genetic aberrations are those affecting only one or a few nucleotides. The human 
genome has a built-in rate of mutation, i.e. alteration of the nucleotide sequence, due to the 
DNA polymerases which replicate the DNA in each cell cycle, have error rates ranging from 
approximately 1/10,000 to 1/100,000 basepairs (bp)39. This means that every individual will 
have some genetic variants that are not found in either of the parents, so-called de novo 
variants. From an evolutionary perspective, this is a good thing as it ensures genetic diversity 
in the population. However, depending on where the errors occur, they can have deleterious 
effects on an individual level. In its strict sense, the word mutation means a nucleotide change 
that is present in less than 1% of the population, and does not infer any information about its 
functional impact. However, the term is commonly used as a synonym to a pathogenic 
variant, which has become a source of confusion. In accordance with current guidelines40, 
mutations will henceforth collectively be referred to as sequence variants, including single 
nucleotide variants (SNVs) and small insertions and deletions (indels). Consequently, a 
pathogenic mutation will be referred to as a pathogenic variant. 
Out of the approximately 3 billion basepairs that constitute a haploid genome, 1.5% compose 
exons of protein-coding genes41. In these genes, nucleotide triplets, i.e. codons, create a code 
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which can be translated into a sequence of amino acids which are the building blocks of 
proteins. A variant in a protein-coding gene can for example give rise to a change in the 
amino acid sequence (missense variant), introduction of a stop codon (nonsense variant), or 
that the reading frame of the codons is shifted (frameshift variant). Disease caused by 
pathogenic variants in protein-coding genes can be either dominant, i.e. one altered allele is 
enough to develop disease, or recessive, i.e. both alleles must be altered for disease to occur. 
The functional impact of a previously unknown variant can be difficult to determine, and is 
also complicated by the fact that not everyone with a deleterious variant will develop disease 
(reduced penetrance), as well as that a disease can cause different symptoms with a varying 
severity in different individuals (variable expressivity).  
In prenatal diagnosis, nucleotide sequence variants have traditionally only been analyzed if 
the parents are known disease carriers. As opposed to numerical variants, which are 
associated with maternal age, de novo SNVs are more commonly transmitted from males, as 
they will accumulate over time in spermatocytes42, on average at a rate of two new SNVs per 
year43. 
1.4 PRENATAL DIAGNOSIS VS PRENATAL SCREENING 
A definitive diagnosis of fetal chromosomal abnormalities during an ongoing pregnancy can 
currently only be achieved by analysis of invasively obtained fetal cells. The invasive 
procedures include amniocentesis, i.e. withdrawal of amniotic fluid, and chorionic villus 
sampling (CVS), i.e. a placental biopsy. CVS has the advantage that it can be performed 
earlier in pregnancy than amniocentesis (week 10-12 vs. week 15-16), but has the 
disadvantage that the placental karyotype in rare cases differs from the fetal, most often as 
confined placental mosaicism (CPM). As both amniocentesis and CVS are invasive methods, 
they are associated with some risks. Although recent data suggest that invasive testing is very 
safe44,45, it has traditionally been burdened with a non-negligible risk of miscarriage, 
commonly stated as 1:20046. Additionally, the invasive procedure is often considered 
unpleasant for the pregnant woman, as well as it is expensive as it requires a fetal medicine 
expert to perform the test. Furthermore, the standard way of identifying chromosomal 
abnormalities in the fetal cells collected by invasive testing is by conventional karyotyping, 
which has some disadvantages. As mentioned previously, the resolution of the analysis is 
low, and the method is also hampered by long turn-around times because of the need for cell 
culture, which is not optimal regarding the time constraints in an ongoing pregnancy.  
Taken together, prenatal diagnosis by invasive testing has never been either intended, nor 
suitable, for large-scale testing. Different screening methods have therefore evolved to 
identify pregnant women at high risk of fetal aneuploidy. As it is known that the aneuploidy 
risk increases with maternal age, an early recommendation was that only women of ≥35 years 
of age should be offered invasive testing. However, age alone is a poor criterion as it only 
identifies 25-30% of fetal aneuploidy47. In the 1990’s, it was shown that the clear space of the 
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fetal neck, the nuchal translucency, was associated with chromosomal abnormalities, where 
higher values inferred a higher risk48. Maternal age together with the nuchal translucency 
measurement, was subsequently combined with concentration measurements of two 
pregnancy associated proteins in maternal blood; pregnancy associated plasma protein A 
(PAPP-A) and human chorionic gonadotropin (hCG). The combination of these parameters is 
known as the first trimester combined test (FCT) which today is a widely used screening test 
for fetal aneuploidy, with a detection rate of approximately 80%, and a false positive rate 
around 5%46,47. The outcome of FCT is a risk assessment of fetal aneuploidy. In Sweden, as 
well as in many other countries where FCT is used, “high risk” is defined as 1:200. In 2014, 
approximately 64% of the women in Stockholm County had an FCT, and 8% had an invasive 
test.  
1.5 NON-INVASIVE PRENATAL TESTING (NIPT) 
Prenatal diagnosis has recently entered a new era because non-invasive prenatal testing 
(NIPT) has become a clinical reality, rapidly spreading worldwide. In 1997, it was discovered 
that cell-free fetal DNA (cffDNA) is present in maternal blood during pregnancy49. This 
discovery was the first step towards NIPT. However it would take several years for the 
method to become successful because of major technical limitations, mainly due to the fact 
that the vast majority of the total cell-free DNA (cfDNA) in maternal plasma derives from the 
pregnant woman herself. In gestational week 10-20, the fetal DNA fraction is on average 10-
15%, but can range from as low as 3% up to 30%50,51. The fetal fraction can be affected by 
several factors, such as maternal weight52 and fetal aneuploidy53,54. 
The first widespread clinical use of NIPT was for two indications, i.e. sex determination55 (in 
case of X-linked disease) and determination fetal Rhesus D (RhD) blood group status56, 
which is important for correct management of RhD negative women carrying an RhD 
positive fetus. Common for these indications is that they both are based on paternally 
inherited alleles, and can therefore relatively easily be identified despite the maternal 
background. Detection of fetal aneuploidy puts higher demands on the method as it requires 
accurate counting of the number of chromosomes, rather than merely determining the 
presence or absence of a certain allele. However, fetal aneuploidy detection has recently been 
enabled by the technical improvement of massive parallel sequencing (MPS). For this task, 
different approaches have evolved, which are either based on whole-genome sequencing 
(WGS)57-59, or different targeted strategies (targeting specific chromosomal regions60 or 
single nucleotide polymorphisms, SNPs61-63). An extra chromosome in the fetus will lead to a 
higher amount of cffDNA derived from that particular chromosome, compared with reference 
chromosomes. By sequencing several million cfDNA fragments and thereafter counting how 
many fragments belong to each chromosome, the aneuploidy can be detected. Aberrant 
cfDNA profiles can however be caused by other factors; analysis with NIPT has for instance 
resulted in presymptomatic identification of cancers in pregnant women, by detection of 
chromosomal abnormalities derived from the tumor64.  
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The detection rates of NIPT regarding fetal trisomies 21, 18 and 13 have been reported to 
99.2%, 96.3% and 91.0%, respectively65. However, the positive predictive value (PPV), i.e. 
the probability that a positive result indeed is true, varies depending on the prevalence of the 
aneuploidy in the pregnant population being tested. For example, in an unselected pregnant 
population, the PPV for trisomy 21 is approximately 50-80%66-68, and hence half of those 
singled out by NIPT may carry a normal fetus. NIPT is consequently not a diagnostic test, 
and a positive test result requires confirmation by invasive testing. However, as the accuracy 
of NIPT is much higher than current other screening methods, the majority of invasive tests 
could be avoided if NIPT was used as the primary screening. 
Although referred to as fetal DNA, the cffDNA mainly derives from apoptotic trophoblasts 
and syncytiotrophoblasts in the placenta69. If future technical improvements will upgrade 
NIPT to a diagnostic test, its accuracy will therefore be similar to CVS.  
1.6 ETHICAL CONSIDERATIONS 
Prenatal diagnosis is a topic that engages many people, and the debate gained new life in 
response to the introduction of NIPT. Concerns have arisen that the test is “too simple” as it 
only requires a simple blood sample from the pregnant woman, and that it therefore could be 
considered a routine sample among others that many would have without sufficient 
reflection70,71, or even that the pressure to have the test might increase as women might feel 
less justified to decline such a simple and risk free test70. Other concerns include the risk of 
trivialization of selective abortions72, and that people with disabilities might face an increased 
stigmatization in the society73. As it has been shown that the complete fetal genome is 
represented in maternal plasma74, there are concerns for a “slippery slope” effect, i.e. that the 
spectrum of traits being tested for will widen, and even include non-medical indications75. On 
the advantageous side, NIPT enables earlier testing, which allows for more time to prepare to 
care for a child with a syndrome, or for earlier pregnancy termination, depending on the 
decision by the parents. Additionally, as stated earlier, primary screening by NIPT drastically 
reduces the need for invasive procedures.  
According to Swedish law, all pregnant women should be offered general information about 
prenatal diagnosis, and women at increased risk of having a child with a genetic disease 
should be offered additional information regarding genetic prenatal testing. Thereafter, it is 
up to the pregnant woman herself if she wants to perform any tests. It is highly important that 
expectant parents are provided sufficient information to be able to make carefully prepared 
choices, regardless if the choice is to do or not to do prenatal testing.  
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2 AIMS OF THE THESIS 
The overall aim of this thesis was to develop and evaluate new procedures to diagnose 
genetic disorders in fetal life, and thereby improve prenatal care and increase our knowledge 
of the normal and abnormal fetal development. 
The specific aims were: 
1) to identify mechanisms causing stillbirth, anatomic abnormalities and tissue calcifications 
using different DNA-based methods (Paper I-III) 
2) to evaluate NIPT using massive parallel DNA sequencing for the analysis of fetal 
aneuploidy; both technically (Paper IV) as well as to evaluate the attitude towards the method 
by pregnant women (Paper V)  
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3 MATERIALS AND METHODS 
3.1 STUDY SUBJECTS 
Due to clinical chromosome analysis which is part of the routine investigation, tissue samples 
from all stillbirth cases in Stockholm have been stored at the Department of Clinical Genetics 
as part of Biobank Karolinska, resulting in a unique material from consecutive stillbirth cases 
during several years. In Paper I, clinical results from chromosome analysis were compiled 
for 481 stillbirths, i.e. all cases that occurred in the Stockholm County during five years; 
2008-2012. A subgroup of 90 cases, corresponding to all cases without a genetic diagnosis 
analyzed in 2010, was additionally analyzed by chromosomal microarray (CMA), to study 
the possible benefits of this method in the analysis of the etiology of stillbirth. In Paper II, 
290 stillbirth cases without a previous genetic diagnosis were analyzed using a gene panel 
including 79 genes associated with various heart conditions and heart development, in order 
to increase our knowledge of the potential role of heart disease in stillbirth. 
In Paper III, 151 fetuses with tissue calcifications were retrospectively identified from the 
archives of the Center for Perinatal Pathology at the Department of Pathology, Karolinska 
University Hospital, corresponding to all cases with registered fetal calcifications during 
2003-2012. For each case, two controls were identified from the same archives. The controls 
were matched for gestational age and type of death (spontaneous or missed abortion, 
stillbirth, induced termination of pregnancy), in order to allow for a matched case-control 
study with the aim of identifying factors associated with fetal calcifications.  
In Paper IV, plasma samples from 31 pregnant women were analyzed using an 
amplification-free protocol for non-invasive prenatal testing (NIPT), to evaluate its ability to 
detect fetal aneuploidies. Fifteen of the samples were donated from women whose fetuses had 
confirmed aneuploidies, whereas 16 were healthy controls. 
Paper V included 1,003 pregnant women recruited at nine maternity clinics located in 
different areas of Stockholm. The women filled in a questionnaire covering awareness, 
attitudes, preferences for risk information and decision-making concerning prenatal 
examinations with emphasis on NIPT, before its introduction into Swedish healthcare. 
3.2 CYTOGENETIC ANALYSIS AND QF-PCR 
Traditional cytogenetic analysis by karyotyping is enabled by culturing cells and chemically 
arresting the cell cycle in metaphase. During this stage, the chromosomes are highly 
condensed, which allows for examination of the individual chromosomes by microscopy. 
Prior to microscopy, the metaphase chromosomes are fixated on a glass slide and stained by 
chromatin staining to visualize each chromosome’s characteristic banding pattern. Using this 
method, chromosomal abnormalities can be detected at a resolution of approximately 5-10 
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Mb. Karyotyping has been the gold standard in prenatal diagnosis of chromosomal 
abnormalities for many years, and has been performed on the majority of fetuses included in 
Paper I-IV. In all cases, at least 11 metaphase nuclei stained with quinacrine (Q) or Giemsa 
(G) banding have been analyzed. In the context of stillbirth, i.e. the area of focus in Paper I 
and II, karyotyping is prone to failure as the fetal tissue has in many cases started to 
macerate, resulting in unsuccessful cell culturing. 
Quantitative fluorescence-polymerase chain reaction (QF-PCR) is a swift and easy way to 
detect aneuploidies of a limited number of chromosomes, usually chromosome 13, 18, 21, X 
and Y. The method is based on analysis of short tandem repeats (STRs), i.e. short fragments 
of DNA that are highly variable in size between individuals. By analyzing STRs located on 
the selected chromosomes, the number of chromosomes can be established. Using this 
method, only numerical aberrations involving the selected chromosomes can be identified, 
and no structural variants can be detected. However, it is a good complement to conventional 
karyotyping as it is not dependent on culturing of cells. In Paper I, QF-PCR was performed 
in all cases where the karyotype analysis had failed, and in Paper III it was used to analyze 
samples from fetuses where no clinical chromosome analysis had been performed previously. 
3.3 CHROMOSOMAL MICROARRAY (CMA) 
During the last decade, methods have been developed to identify chromosomal abnormalities 
at a higher resolution than conventional karyotyping and QF-PCR. Among these methods are 
the chromosomal microarrays (CMAs), such as array-based comparative genomic 
hybridization (array-CGH). The high resolution of these methods enables detection of CNVs 
(deletions and duplications) even at the level of single exons of known disease genes in 
targeted array formats. Patient and reference DNA are labeled with different fluorophores 
(commonly the cyanine dyes Cy3 and Cy5), and thereafter simultaneously hybridized to 
oligonucleotide probes printed on a microarray glass slide. The probes are designed to 
hybridize to DNA fragments located in the genomic areas of interest, which can either be 
evenly distributed across the complete genome, or in specifically targeted areas. Following 
hybridization, the slide is washed and scanned, and the fluorescent signals from both dyes are 
measured. A global normalization of the total signal from each dye is performed, whereupon 
the signals from each probe is measured and a log2 ratio between the signals is calculated. 
The signal intensity will be proportional to the concentration of DNA, and therefore 
differences in copy number between patient and reference DNA can be detected (Figure 2). 
Hence, the method can only detect unbalanced rearrangements, and thus not e.g. inversions or 
balanced translocations. However, the majority of these events are unlikely to cause a clinical 
phenotype in the carrier. 
The resolution of the analysis is directly corresponding to the number and distribution of 
probes. In Paper I, an 180K oligonucleotide array with evenly distributed whole-genome 
coverage (Oxford Gene Technology), with a practical resolution of 20-50 kilobases (kb, 
thousands of basepairs), was used in the analysis. The same platform was also used to 
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investigate a sample which gave an unexpected result in Paper IV. The criterion for 
considering an aberration for analysis was that at least three consecutive probes had log2 
ratios outside the normal range, where the threshold was 0.35 for duplications and -0.65 for 
deletions. For the detection of mosaic aberrations, a threshold of +/-0.1 was used with a 5 Mb 
cutoff. Aberrations were detected using a circular binary segmentation (CBS) aberration 
detection algorithm and additional manual interpretation/curation. 
Figure 2. The principle of array-CGH. Patient and reference DNA are labeled with different 
fluorescent dyes and are thereafter allowed to simultaneously hybridize to oligonucleotide 
probes printed in spots on a microarray glass slide (A). Following hybridization, the color of 
each spot reflects the ratio between patient and reference DNA (B). The array slide is 
scanned, and the fluorescent signal for each dye is measured. The signal intensities are 
translated into a log2 ratio between patient and reference DNA, which is used in the analysis 
(C).  
3.4 ANALYSIS OF CMA DATA 
The interpretation of CNVs identified by CMA might be a challenging task, as their clinical 
relevance is often not obvious. A CNV can be considered pathogenic if it overlaps with a 
known syndrome region or genes known to cause disease. However, the challenge is that 
most CNVs are benign normal variants that are found in the general population. It has been 
estimated that approximately 12% of the human genome is covered by CNVs76, but the 
proportion is likely higher as the definition was recently updated. The traditional definition of 
a CNV is that it should be at least 1 kb in size, but according to the new definition a CNV can 
be as small as 50 bp77. In cases where an identified CNV neither overlaps with a known 
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syndrome or disease region, nor a known normal variant, three major considerations are 
normally taken into account when trying to interpret its clinical relevance: inheritance, size 
and gene content. If a CNV is inherited from an unaffected parent, it is most likely benign. 
Studies suggest than more than 99% of benign CNVs are inherited, and that the vast majority 
of these are smaller than 500 kb. In contrast, most pathogenic CNVs are of de novo origin and 
larger than 1 Mb78. In general, CNVs affecting many genes are more likely to result in a 
clinical phenotype compared with those only affecting a few, as well as that loss of genes, i.e. 
a deletion, is generally more likely to be harmful than extra copies, i.e. a duplication, of them. 
However, for many of the recurrent microdeletion syndromes, a duplication of the same 
region also leads to a recognized syndrome. In Paper I, interpretation of the identified CNVs 
was complicated by the fact that no parental samples were available. Inheritance could 
therefore not be taken into consideration. 
Classification of CNVs, from benign to pathogenic, was performed in accordance to 
previously described guidelines79, with minor modifications. Briefly, identified CNVs were 
compared to published data sets, e.g. the CNV morbidity map described by Cooper et al in 
201138, and databases such as the Database of Genomic Variants (DGV, 
http://projects.tcag.ca/variation), the International Standards for Cytogenomic Arrays 
Consortium (ISCA, http://dbsearch.clinicalgenome.org/), and the Database of Genomic 
Variation and Phenotype in Humans using Ensembl Resources (DECIPHER, 
https://decipher.sanger.ac.uk/). Also in-house data of postnatal CMA results from the 
Department of Clinical Genetics (including ~2,500 samples, mainly from patients with 
intellectual disability and/or congenital malformations) and data from 1,100 healthy blood 
donors were used for comparison. In addition, factors such as size, copy number status, and 
gene content were considered.  
3.5 HALOPLEX LIBRARY PREPARATION 
Recently, technologies have emerged that enable high throughput DNA sequencing. These 
techniques are collectively known as massive parallel sequencing (MPS) or next generation 
sequencing (NGS). Prior to the sequencing itself, a sequencing library that contains the DNA 
fragments of interest must be prepared. Different approaches can be used to fulfill this task. 
One option is to sequence the whole genome (whole genome sequencing, WGS) or all coding 
parts of a genome, i.e. the exome (whole exome sequencing, WES). However, in cases where 
a limited number of genes are of interest, library preparation of gene panels might be the 
preferable choice. 
In Paper II, a gene panel containing 79 genes involved in heart disease and heart 
development was utilized, in order to study the potential role of heart disease in stillbirth. The 
genes were selected according to available literature, and were reported to be associated with 
channelopathies, cardiomyopathies or congenital heart defects (CHD). The Agilent HaloPlex 
target enrichment system was used to prepare libraries containing the exons and exon-intron 
boundaries of the selected genes. The outline of the method is displayed in Figure 3. Genomic 
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DNA is cleaved by using a cocktail of restriction enzymes to obtain short DNA fragments. 
Following restriction, a multitude of biotinylated probes are added to the DNA. The probes 
include DNA sequences that will specifically hybridize to the DNA of interest. By making 
use of the high affinity between biotin and streptavidin, the DNA-probe complexes are 
captured by using streptavidin-coated magnetic beads. The captured DNA fragments are 
amplified by polymerase chain reaction (PCR) to obtain multiple copies, which after 
purification is ready for sequencing. 
 
Figure 3. The principle of HaloPlex. Genomic DNA is fragmented using a cocktail of 
restriction enzymes (A). Biotinylated HaloPlex probes are added to the short DNA fragments 
(B). The probes contain complementary sequences to the DNA of interest (black), and will 
therefore hybridize to form circular DNA-probe complexes (C). The complexes are captured 
by using streptavidin-coated magnetic beads, whereupon the probes are ligated to the DNA 
(D). By using primers complementary to incorporated probe sequences (green and purple) 
(E), the DNA circles are amplified by PCR (F). The amplified library is sequenced (G), and 
analysis of identified nucleotide variants is performed (H).  
3.6 AMPLIFICATION-FREE NIPT LIBRARY PREPARATION 
Cell-free DNA (cfDNA) has some characteristic properties. It consists of short fragments, 
typically 160-200 bp, and is partially single-stranded. In that sense, it resembles ancient 
DNA. In Paper IV, a library preparation protocol originally created for ancient DNA80,81 was 
modified to allow for amplification-free NIPT. Current other MPS-based NIPT methods 
include amplification of the DNA by PCR. A problem with PCR is that it inevitably leads to a 
bias due to some DNA fragments being amplified more efficiently than others. By 
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eliminating the PCR bias, the accuracy of NIPT could potentially increase. The amplification-
free protocol was evaluated on 31 clinical samples, of which 15 had confirmed trisomies. The 
blood samples had been donated from women with high risk pregnancies according to FCT. 
The samples were centrifuged shortly after blood draw to collect the plasma, whereupon 
cfDNA was extracted.  
As opposed to the HaloPlex library preparation, there is no need for restriction enzyme 
treatment in this protocol, as the cfDNA is already fragmented. Instead, the cfDNA is 
immediately denatured and dephosphorylated, and a biotinylated linker is ligated directly to 
each DNA fragment. The DNA-linker complexes are bound to streptavidin-coated magnetic 
beads, whereupon a single-stranded adaptor is added. The adaptor is complementary to the 
linker and will therefore hybridize to the DNA-linker complexes. The adaptor is extended by 
a polymerase to create a complementary strand to the cfDNA, which thereby becomes 
double-stranded. A second, double-stranded, adaptor is added and ligated to the DNA by 
blunt end ligation. The DNA is thereafter denatured, and the free DNA strand, i.e. the strand 
that is not bound to the magnetic bead, is collected for sequencing.  
3.7 MASSIVE PARALLEL SEQUENCING (MPS) 
The technology used to sequence the libraries yielded by both HaloPlex and the 
amplification-free NIPT protocol was Illumina’s sequencing-by-synthesis method, utilizing 
reversible termination chemistry. The DNA library to be sequenced is denatured and added to 
a lane in a flowcell. The lane is covered by covalently bound adaptors that will hybridize to 
the library fragments. The adaptors also work as PCR primers, used to enable amplification 
of the hybridized library fragments to create dense clusters containing multiple identical 
copies. The cluster generation is required to increase signal intensity. Following cluster 
generation, the DNA fragments are denatured once more to enable the sequencing reaction. A 
universal sequencing primer is added, and extended by one nucleotide at a time. To ensure 
that only one nucleotide is incorporated in each cycle, they are modified with a terminator 
that blocks further elongation. Additionally, each nucleotide is labeled with a specific 
fluorophore. Following incorporation of a nucleotide, the fluorescent signal from each cluster 
is recorded, whereupon the terminator is cleaved off to allow for a new cycle of nucleotide 
incorporation82. 
3.8 ANALYSIS OF MPS DATA 
Both the HaloPlex and the amplification-free NIPT libraries were made for the purpose of 
MPS. However, the desired data was completely different. In the case of HaloPlex, the 
sequence itself is of interest, and a deep coverage of the selected genes was required to 
identify sequence variants with high accuracy. Conversely, NIPT is a counting assay, which 
means that as long as the reads can be mapped to the reference genome, the sequence itself is 
not important, but rather the number of sequenced DNA fragments. 
17 
 
3.8.1 HaloPlex data analysis 
A custom script pipeline originally created for analysis of HaloPlex sequencing data 
generated from the Illumina MiSeq instrument, was utilized to identify sequence variants in 
the 79 genes associated with heart disease and development included in the gene panel. 
Previously published data have shown that the custom script yields results of higher quality 
than other pipelines used as common practice for analysis of MPS data83. The custom script 
was originally created in order to achieve a faster analysis procedure, as well as to remove 
reads of low quality.  
The basis of the original custom script is that MiSeq HaloPlex sequence reads are generally 
of very high quality. The first step is to sort the sequence reads, and map them against each 
other. Reads of poor quality are expected to vary between themselves in a random fashion, 
due to sequencing errors. By only taking identical reads recurring ≥3 times in the data into 
account, reads of poor quality are sorted out. For each group of identical reads, one 
representative is mapped against the human genome (version GRCh37/hg19). By aligning 
only one representative for each read instead of thousands of identical copies, a vast amount 
of computer times is saved, resulting in a total run time of only a few minutes per sample, 
including computation of coverage and variant calling. However, in Paper II, the NextSeq 
instrument was used, requiring modifications of the protocol, due to that reads generated  
from NextSeq have a higher frequency of erroneous base calls. Instead of removing reads 
with low quality bases, the low quality base calls were N-substituted and paired-end analysis 
was performed without pooling of identical read pairs. Variants were called when the ratio of 
reads including the variant divided by the total number of reads at the specific position was 
≥0.25 for SNVs and ≥0.12 for insertions and deletions.  
The identified variants were filtered to exclude variants occurring at a frequency of >1% in 
population databases, as were synonymous variants, and intronic variants that were not 
predicted to affect splicing. The remaining variants were individually evaluated based on 
available literature, type of variant (missense, loss-of-function variant), entries in the Human 
Gene Mutation Database (www.hgmd.org), ClinVar (www.ncbi.nlm.nih.gov/clinvar/) and 
dbSNP (www.ncbi.nlm.nih.gov/SNP/), and evolutionary conservation. Additionally, the 
Combined Annotation Dependent Depletion (CADD) score was used to assess the 
deleteriousness of the variants84. Compared with other tools used to predict functional effects 
of genetic variants, CADD has the advantage that it combines several different annotations to 
create a single score. The scaled CADD score, which was used in this study, relates the 
variant of interest to all possible theoretical variants in the genome, whereupon a logarithmic 
score is returned. A score of 20 indicates that the variant is among the 1% most deleterious 
variants in the genome, 30 indicates that it is among the 0.1% most deleterious variants, and 
so on.  
A variant was classified as pathogenic if it was either a loss-of-function (LoF) variant, or a 
missense variant where previously published data suggested an association between the 
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variant and the disease of interest. Conversely, missense variants for which no data 
supporting pathogenicity had been published, and which additionally were located at poorly 
conserved positions and had a low CADD score, were considered likely benign and excluded 
from further evaluation. Missense variants which did not fall into either of these categories 
were considered to be of unknown clinical significance. 
3.8.2 Amplification-free NIPT data processing 
The amplification-free NIPT protocol was used on 31 samples, of which 15 had confirmed 
trisomies. Four female samples were used for normalization. One of the normalization 
samples was used to create windows containing 10,000 amplification-free reads (AFRs) in 
each. The same windows were applied on the remaining normalization samples, and the mean 
number of AFRs in each window was calculated and used for normalization of the rest of the 
samples. The number of reads per window was centered around one, based on the average 
number of reads per window on all chromosomes, with the exception of sex chromosomes, 
potential trisomy chromosomes 13, 18 and 21, as well as chromosome 16 and 19 that 
sometimes showed an irregular number of reads. Loess local regression was performed to 
correct for residual GC bias, and the 10% windows with lowest and highest normalized read 
counts (NRCs) were excluded to get rid of outliers. 
3.9 QUESTIONNAIRE 
NIPT was introduced at the Department of Clinical Genetics, Karolinska University Hospital, 
in June 2015. Thereby it became the first NIPT service available via national health care in 
the Nordic countries. When introducing a new method, it is of value to study the interest, 
potential uptake, and how the method may be accepted by the prospective users. In Paper V, 
we developed a questionnaire to be answered by pregnant women, covering awareness, 
attitudes, preferences about risk information and decision-making concerning prenatal 
examinations, with emphasis on NIPT. Additionally, attitudes towards having a child with a 
chromosomal abnormality were studied, as well as the women’s self-perceived likelihood for 
that event to occur. The questionnaire contained background questions as well as multiple-
choice questions and Likert scales covering the different topics. Women were recruited to fill 
in the questionnaire at nine maternity clinics located in different areas of Stockholm, selected 
to represent a broad variety in socioeconomic status of the participants.  
3.10  STATISTICAL ANALYSES 
Various statistical analyses have been used in the studies included in this thesis, of which the 
majority has been performed in order to identify significant differences in proportions of 
various test statistics between different cohorts or subgroups. In Paper I, II and V, Fisher’s 
exact test has been performed in cases where there are two different outcomes, whereas the 
chi2 test has been used in cases of multiple outcomes. Because of the study design, 
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McNemar’s test for matched case-control studies was performed to identify differences 
between subgroups in Paper III.  
In Paper II, the frequency of SNVs identified in the 290 investigated stillbirth cases was 
compared with variant frequency data reported by the Exome Aggregation Consortium 
(ExAC, www.exac.broadinstitute.org), which includes exome sequencing data from more 
than 60,000 individuals. The proportion of pathogenic SNVs was compared between the 
stillbirth cohort and ExAC by using Fisher’s exact test as described above. However, that 
calculation was based on the SNVs that actually had been identified in the study cohort, and 
in order to get an approximation of the proportion of pathogenic SNVs in relation to the total 
number of SNVs in the different cohorts, a Monte Carlo permutation test was performed. The 
test included 10,000 iterations, in which groups of 50 variants from each cohort were 
randomly drawn. The number of pathogenic SNVs in each group was counted, whereupon 
the mean proportion of pathogenic SNVs across the 10,000 iterations was calculated. The 
difference between means of proportion of pathogenic SNVs for the stillbirth cohort and 
ExAC was thereafter calculated, and a 95% confidence interval (CI) based on the binomial 
distribution was established in order to investigate the null hypothesis that there was no 
difference in means. The obtained proportions of pathogenic SNVs in both the study cohort 
and ExAC was used to calculate the expected proportion of pathogenic SNVs if another 
cohort of cases would have been drawn from the same binomial distributions.  
Results from the different analyses were considered statistically significant when p<0.05. 
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4 RESULTS AND DISCUSSION 
4.1  CHROMOSOMAL ABNORMALITIES IN STILLBIRTH (PAPER I) 
Using traditional karyotyping or QF-PCR, chromosomal abnormalities were identified in 
7.5% (n=36) of the 481 stillbirth cases included in Paper I. This is consistent with what has 
been published previously6. The distribution of chromosomal abnormalities is displayed in 
Figure 4.  
 
Figure 4. Chromosomal abnormalities in stillbirth. Distribution of aberrations identified in 
36 out of 481 stillbirth cases (7.5%) by using either karyotyping or QF-PCR.  
Analysis with CMA of 90 cases additionally identified two known microdeletion/-duplication 
syndromes, one aberration disrupting a known disease-gene associated with the observed 
phenotype in the particular stillbirth case, and 29 variants of unknown significance (VOUS), 
of which none could have been detected using conventional karyotype analysis. One of the 
known syndrome associated aberrations was a 3.7 Mb deletion located on chromosome 17, 
associated with Smith-Magenis syndrome (Figure 5). Features of Smith-Magenis syndrome 
include characteristic facial features, intellectual disability, behavioral problems and sleep 
disturbances, as well as feeding difficulties and failure to thrive85. This aberration may have 
contributed to the fetal demise, as it affects several neurological and developmental 
processes. The second syndrome associated aberration was a 523 kb duplication located on 
chromosome 16, associated with the 16p11.2 duplication syndrome (Figure 5). Aberrations in 
this region are identified in up to 1% of patients with autism spectrum disorders86,87, but also 
other neuropsychiatric disorders, such as schizophrenia88 and epilepsy89. The aberration is 
unlikely to have caused the fetal demise, however detecting aberrations of this kind may be of 
value for the extended family as they are often inherited by an unaffected or only slightly 
affected parent, and may cause symptoms in a future child86. The aberration affecting a 
known disease-gene was a small duplication, 23 kb in size, located on chromosome 14 
(Figure 5). The duplication likely disrupts the genes MYH6 and MYH7. Studies have shown 
that defects in MYH6 can cause atrial septal defect90,91 – a congenital heart defect (CHD) that 
was identified in the stillborn fetus. 
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In addition to the known syndrome- or disease associated CNVs, 29 VOUS were identified. 
Nine of the VOUS, in eight stillbirth cases, were 500 kb or larger. As mentioned previously, 
reports have suggested that more than 99% of benign variants are inherited, and that the 
majority of them are smaller than 500 kb78. Based on this, the VOUS larger than 500 kb 
identified in our cohort are the most likely to be pathogenic. Unfortunately, the inheritance 
pattern could not be determined as parental samples were not available. However, one of the 
smallest aberrations that were detected was most probably pathogenic, i.e. the duplication 
disrupting MYH6. This illustrates the importance of evaluating all aberrations, regardless of 
size.  
 
 
 
  
 
 
Figure 5. Known syndrome or disease 
associated aberrations identified by CMA. 
A heterozygous deletion located on 
chromosome 17, associated with Smith-
Magenis syndrome (top left), a heterozygous 
duplication located on chromosome 16 
associated with the 16p11.2 duplication 
syndrome (top right), and a heterozygous 
duplication located on chromosome 14, 
disrupting the genes MYH6 and MYH67 
(bottom left). 
4.2 PERFORMANCE BY DIFFERENT CHROMOSOME ANALYSIS 
METHODS IN STILLBIRTH INVESTIGATION (PAPER I) 
Using conventional karyotyping, results were obtained in 391 out of the 481 of the stillbirth 
cases included in the study (81.3%). QF-PCR yielded a result in 86 of the remaining cases. 
In four cases, both karyotyping and QF-PCR failed. Analysis with CMA on 90 samples 
yielded results of excellent quality in 100% of the cases, i.e. a significantly higher success 
rate than karyotyping (p<0.001). Excellent was defined as a derivative log ratio (DLR) 
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spread below 0.15, according to recommendations from the manufacturer. Interestingly, the 
excellent results were true also for DNA samples which were highly degraded according to 
results from gel electrophoresis.  
Chromosomal aberrations were identified in 7.5% of the stillbirth cases by using karyotype 
analysis. Based on the aberrations identified in this cohort, QF-PCR would have yielded a 
chromosomal aberration detection frequency of 5.8% if it had been used on all samples. Our 
results suggest that comparative genomic hybridization based CMA could potentially 
increase the detection frequency in stillbirth from 7.5% to 10-20%, based on an additional 
detection of 3% known syndromes/monogenic disorders (lower span), and the detection of 
VOUS ≥500 kb (higher span). However, array-CGH would fail to detect the polyploidies as 
the increase in chromosome material is even across the whole genome. Using a standard 
reference sample, this type of array will only indicate the presence of potential polyploidy if 
there is a deviating ratio between the sex chromosomes, e.g. 69,XXY, which was not the case 
for any of the polyploidies identified in this cohort. 
4.3 ASSOCIATION BETWEEN MATERNAL AGE AND STILLBIRTH 
(PAPER I) 
An association between advanced maternal age and stillbirth has been shown in several 
previous studies92-95, and the same pattern was true also in our material. The proportion of 
stillbirths in different maternal age groups corresponded well to the proportion of child births 
by the same age groups in Stockholm, except for women ≥40 years of age, in which stillbirth 
was significantly overrepresented (p<0.001). Additionally, the proportion of stillbirth cases 
with chromosomal abnormalities was significantly higher in this age group (19.5%, p=0.006). 
This is not surprising as it is well known that the risk of chromosomal abnormalities increases 
with maternal age. Interestingly, the lowest proportion of aberrations, 2.9%, was identified in 
women of 35-39 years of age.  
4.4 PATHOGENIC VARIANTS ASSOCIATED WITH HEART DISEASE 
IDENTIFIED IN STILLBIRTH (PAPER II) 
We analyzed 290 stillbirth cases without known chromosomal abnormalities with a 
customized HaloPlex gene panel, including 79 genes involved in heart disease and heart 
development. Of the investigated cases, 62 (21.4%) harbored one (n=58) or two (n=4) 
variants with evidence supporting pathogenicity, i.e. LoF variants (nonsense, frameshift or 
splice site substitutions), evidence from functional studies, or previous identification of the 
variants in affected individuals. The proportion of individuals harboring the same variants 
reported in ExAC was significantly lower, 7.94% (p<0.001, Figure 6). Fifty-three percent of 
the identified pathogenic variants were located in channelopathy genes, 24% in 
cardiomyopathy genes, and 23% in genes mainly associated with congenital heart defects 
(CHD).  
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Figure 6. Proportions of individuals with pathogenic SNVs in the study cohort, 
compared with the corresponding proportions in ExAC for the same variants. 
***=p<0.001, **=p<0.01 
The genes included in the panel, as well as the specific genes in which pathogenic SNVs 
were identified, are displayed in Table 1. In addition to the variants with evidence supporting 
pathogenicity, 174 missense variants of unknown significance were identified in 125 stillbirth 
cases. 
Table 1. Genes included in the customized HaloPlex gene panel, their associated 
diseases, and identified pathogenic SNVs. 
Category Disease 
Genes with identified pathogenic 
SNVs (n=number of variants) 
Genes with no identified 
pathogenic SNVs 
C
a
rd
io
m
y
o
p
a
th
ie
s
 
ARVC DSG2 (n=2), DSP (n=2), PKP2 (n=1) DSC2, JUP, TGFB3, TMEM43 
DCM 
ABCC9 (n=1), BAG3 (n=1), DES 
(n=1), NEBL (n=1), NEXN (n=1), 
TNNI3 (n=1) 
ACTN2, ANKRD1, DMD, DNAJC19, 
FHL2, LDB3, LMNA, PLN, RBM20, 
TAZ, TCAP, TMPO, TNNC1 
HCM 
CSRP3 (n=1), MYBPC3 (n=2), MYH7 
(n=1), TTN (n=1) 
ACTC1, BRAF, CALR3, CAV3, GLA, 
JPH2, LAMP2, MYL2, MYL3, 
MYLK2, MYOZ2, PRKAG2, TNNT2, 
TPM1, VCL 
C
h
a
n
n
e
lo
p
a
th
ie
s
 LVNC  DTNA, MIB1 
BrS 
CACNB2 (n=1), GPD1L (n=4), HCN4 
(n=5), KCNJ8 (n=1), TRPM4 (n=4) 
CACNA1C, CACNA2D1, KCNE3, 
SCN1B, SCN3B, SCN4B 
CPVT CASQ2 (n=1), RYR2 (n=1)  
LQTS 
ANK2 (n=5), KCNH2 (n=3), KCNQ1 
(n=5), SCN5A (n=3) 
AKAP9, KCNE1, KCNE2, KCNJ2, 
KCNJ5, SNTA1 
CHD 
GATA4 (n=9), GATA5 (n=5), 
NOTCH1 (n=1) 
FBN2, FGF16, HRAS, MAP2K2, 
MYH6, TBX5 
ARVC: arrhythmogenic right ventricular cardiomyopathy, BrS: Brugada syndrome, CHD: congenital 
heart defects, CPVT: catecholaminergic polymorphic ventricular tachycardia, DCM: dilated 
cardiomyopathy, HCM: hypertrophic cardiomyopathy, LQTS: long QT syndrome, LVNC: left 
ventricular non-compaction cardiomyopathy 
0%
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Genes in which at least five pathogenic SNVs were identified were searched in ExAC, and all 
reported missense and LoF variants were systematically searched for in the ClinVar database, 
in order to get a crude approximation of how common pathogenic SNVs are in the general 
population for these genes. ClinVar is a public archive containing reports of the relationships 
between human variations and phenotypes, together with supporting evidence. The results 
showed a significantly higher total number of observations of pathogenic alleles in KCNQ1 in 
relation to wild type alleles in the study cohort compared with ExAC (0.86% vs. 0.29%, 
p=0.0289), whereas no significant difference was seen for the other genes analyzed (0.86% 
vs. 1.25%, p=0.5709 for ANK2, 1.55% vs. 0.81%, p=0.5932 for GATA4, and 0.86% vs. 
0.41%, p=0.0908 for GATA5, respectively).  
Previous studies have mainly focused on stillbirth in association with channelopathies, and 
especially long QT syndrome (LQTS). LQTS affects cardiac ion channels, and is 
characterized by a prolonged Q-T interval on echocardiogram. The condition is a common 
cause of sudden death postnatally96, and is diagnosed in up to 9.5% of infant death syndrome 
cases97. Crotti et al studied 91 stillbirth cases for SNVs in the most common LQTS 
susceptibility genes, i.e. KCNQ1, KCNH2 and SCN5A. They identified putative pathogenic 
variants in 3.3% of their cases98, and the proportion of putative pathogenic SNVs for the same 
genes in our study was very similar; 3.7% (n=11). One variant, KCNQ1, p.Arg397Trp, was 
identified in both studies, and it has been shown to cause a significant reduction in current 
densities across the potassium channel encoded by KCNQ1, compared with the wild type 
channel98. Furthermore, the total number of pathogenic alleles in KCNQ1 observed in our 
cohort was significantly higher than in ExAC (p=0.0289), which supports that SNVs in this 
gene might play a role in stillbirth. In addition to the most common LQTS genes, five cases in 
our cohort harbored SNVs in ANK2. However, the frequency of pathogenic SNVs in ANK2 
identified in our cohort did not differ significantly to the frequency in ExAC. This might 
reflect that ANK2 is mainly associated with LQTS type 4, which phenotypically is highly 
variable and may go unnoticed throughout life99. 
Pathogenic SNVs in genes associated with catecholaminergic polymorphic ventricular 
tachycardia (CPVT) were identified in four cases (1.4%), of which three were located in 
RYR2 and one in CASQ2. CPVT is one of the most severe cardiac channelopathies, and is 
characterized by ventricular arrhythmias causing syncope, cardiac arrest and sudden cardiac 
death, predominantly in young patients including infants100,101. Therefore, these SNVs are 
good candidates for being associated with stillbirth. Additionally, SNVs associated with 
Brugada syndrome (BrS) were identified in 15 cases (5.2%). BrS has mainly been described 
in association with sudden death in adults previously, and therefore its role in stillbirth is 
difficult to interpret. However, two SNVs, located in GPD1L and HCN4, are worth 
highlighting. The GPD1L variant p.Ile124Val was found in four cases in our cohort, resulting 
in a MAF of 0.69%, which is more than 3 times higher than the MAF of 0.21% reported in 
ExAC (p=0.0333). The HCN4 variant p.Val759Ile was identified in five cases, resulting in a 
MAF of 0.86%, i.e. a 2.5 fold increase compared with the corresponding number, 0.35%, in 
ExAC (p=0.0570). Both these variants have been associated with sudden infant death 
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syndrome (SIDS) in previous studies102,103. Although the latter of the variants did not quite 
reach statistical significance, the increased frequency of these SNVs in our cohort might 
indicate that they are risk factors for stillbirth as well as SIDS. 
SNVs with evidence supporting pathogenicity in genes associated with cardiomyopathies 
were identified in 15 cases (5.2%). Cardiomyopathies, i.e. disorders of the heart muscle, are 
impairments of the ability of the myocardium to contract, which can result in heart failure104. 
In general, cardiomyopathies are progressive disorders which are not detected during the 
early years of life, and have therefore not been studied in association with stillbirth 
previously. However, studies suggest that they might play a role in SIDS. Brion et al studied 
286 SIDS cases for variants in genes associated with hypertrophic cardiomyopathy (HCM) 
and found variants with possibly damaging effects in 4% of the cases105. One of their 
identified SNVs, MYBPC3, p.Ala833Thr, was detected in two of our cases. Brion et al 
hypothesized that their identified variants might cause sudden cardiac death even in the 
absence of a cardiac phenotype, but they did also emphasize the possibility that the variants 
could be non-disease causing rare variants105. 
Congenital heart defects (CHD) is the group of malformations that is most common in live 
born infants106,107, and is additionally the most frequent cause of infant death resulting from 
birth defects108. Fifteen cases in our cohort (5.2%) had variants in genes mainly associated 
with CHD (i.e. GATA4, GATA5 and NOTCH1). Autopsy had been performed on 13 of these 
15 cases, and the only heart malformation detected was an atrial septal defect in the fetus with 
the variant in NOTCH1; a gene that has mainly been associated with aortic valve 
anomalies109. Hence, the clinical significance of these SNVs is difficult to interpret. 
Additionally, the frequency of pathogenic SNVs identified in GATA4 and GATA5 in our 
cohort did not differ significantly from the frequencies reported by ExAC. However, variants 
in GATA4 have also been associated with atrial fibrillation in addition to structural heart 
malformations110. 
In order to compare the proportion of pathogenic SNVs in the stillbirth cohort to ExAC 
across all 79 genes included in the gene panel, a Monte Carlo permutation test with 10,000 
iterations was performed. In each iteration, 50 variants were randomly drawn from the 
stillbirth cohort and ExAC, and the average proportions of pathogenic SNVs were calculated. 
In the stillbirth cohort, the average proportion was 0.0351, whereas the corresponding 
proportion in ExAC was 0.0235. The difference in average proportions is hence 0.0117, with 
a 95% CI of [0.01, 0.0135]. As the confidence interval does not include 0, the null 
hypothesis, i.e. that the proportion does not differ between the stillbirth cohort and ExAC, can 
be rejected. The obtained proportions were used to calculate the expected proportion of 
pathogenic SNVs if new cohorts would be drawn from the same binomial distributions. If 
drawn from a population with similar characteristics as ExAC, the expected proportion would 
be 13.2%, with a 95% CI of [9.4%, 17.2%]. The proportion of pathogenic SNVs identified in 
our study, 21.4%, thus lies outside the expected range for a cohort similar to ExAC. If instead 
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a cohort would be drawn from a population similar to the stillbirth cohort included in the 
study, the expected proportion would be 19.3%, with a 95% CI of [14.8%, 23.8%]. 
Taken together, our findings indicate a modest but significantly increased frequency of 
pathogenic SNVs in stillbirth compared to what is reported by ExAC, and gives further 
support to the hypothesis that channelopathies, and potentially also cardiomyopathies and 
CHD, might be associated with stillbirth. Additional studies, where parental samples, 
comparable control groups, and functional analyses are included, are required to further 
establish an association between stillbirth and heart disease. Furthermore, because of the high 
frequency of variants of unknown significance, clear guidelines regarding how to handle 
these findings are necessary before the method is suitable for implementation in clinical 
practice. 
4.5 CHROMOSOMAL ABNORMALITIES IN FETUSES WITH TISSUE 
CALCIFICATIONS (PAPER III) 
The proportion of fetuses with tissue calcifications in the archives of the Department of 
Pathology was 5.3%, and the calcifications were mainly located in the liver (57%), but also in 
heart (13%), bowel (6%), or even multiple tissues (22%). Fetuses with calcifications showed 
a significantly higher frequency of chromosomal abnormalities compared with controls; 50% 
vs. 20% (p<0.001). The most frequent aberrations included trisomy 21 (33%), trisomy 18 
(22%), and monosomy X (18%). The distribution of chromosomal abnormalities was similar 
in controls with aberrations.  
The fetuses were divided into different subgroups, based on gestational age, type of death, 
and tissue location of calcifications. Regarding gestational age, the highest proportion was 
seen in fetuses <14 gestational weeks (71%) and lowest in week ≥29 (17%). Regarding type 
of death, the highest proportion was seen among cases after induced termination (63%). This 
was expected because a common reason for pregnancy termination followed by autopsy is 
chromosomal abnormalities. The lowest frequency was observed in the stillbirth group 
(31%). However, note that this “low” proportion is more than three times higher than the 
overall proportion of chromosomal abnormalities in stillbirth, according to results in Paper I. 
No difference in proportions was observed in subgroups based on tissue location of 
calcifications. 
The prevalence of fetal malformations was significantly higher in cases than in controls (72% 
vs. 50%, p<0.001). When divided into groups based on the presence of chromosomal 
abnormalities or not, the difference in malformation prevalence was only seen between cases 
and controls with chromosomal abnormalities (95% vs. 77%, p=0.004). The corresponding 
numbers in cases and controls without chromosomal abnormalities were 49% vs. 43% 
(p=0.446). It was expected that fetuses with chromosomal abnormalities would have a higher 
prevalence of malformations than those without, but the discrepancy in prevalence between 
cases and controls is notable. These results could indicate that calcification is a part of the 
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phenotypic spectrum caused by various chromosomal abnormalities, and is more likely to 
occur in fetuses with a more severe phenotype. When analyzed from the opposite direction, 
i.e. the proportion of chromosomal abnormalities in cases and controls with or without 
malformations, cases with malformations had a significantly higher proportion of 
chromosomal abnormalities compared with controls, (66% vs. 31%, p<0.001). Cases and 
controls without malformations showed equal proportions of chromosomal abnormalities 
(10% vs. 9%). In practice, our results suggest that if a fetus has a calcification and a 
malformation, the probability of a chromosomal abnormality is increased by more than 
double, compared with if the fetus has a malformation only. 
4.6 PERFORMANCE OF AMPLIFICATION-FREE NIPT (PAPER IV) 
The amplification-free NIPT method correctly identified all autosomal trisomies, which 
included one case of trisomy 13, four cases of trisomy 18, and eight cases of trisomy 21. 
Additionally, it could correctly determine the number of X chromosomes in both normal XX 
and XY samples, as well as in one case of X0 (Turner syndrome) and one case of XXY 
(Klinefelter syndrome). However, in one case for which standard cytogenetic testing had 
confirmed the presence of both trisomy 18 and XXY, NIPT failed to identify the additional X 
chromosome (Figure 7).  
 
 
Figure 7. Results from amplification-free NIPT. The method could correctly identify all 
chromosomal abnormalities previously identified by karyotyping or QF-PCR, except for one 
case of XXY where NIPT failed to detect the extra X chromosome (arrow). NRC = 
normalized read count.  
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To understand why the additional X chromosome was not detected, lung tissue from the fetus 
was obtained from the Department of Pathology, Karolinska University Hospital. DNA was 
extracted followed by analyses by array-CGH and amplification-free sequencing. The 
additional analyses showed that the fetus actually was mosaic; 70% of the cells carried the 
extra X chromosome, while 30% carried normal male sex chromosomes (XY). The presence 
of trisomy 18 was confirmed in 100% of the cells by the additional analyses. The mosaicism 
probably explains why the additional X chromosome was not identified using the 
amplification-free protocol. As cffDNA mainly is derived from the placenta, it would have 
been optimal if placental DNA could have been analyzed, but unfortunately no such tissue 
was available. However, considering the mosaic status of the fetus, it is possible that the XY 
profile identified by NIPT reflected the placental status, rather than a technical error. 
4.7 PREGNANT WOMEN’S ATTITUDES TOWARDS PRENATAL 
EXAMINATIONS WITH EMPHASIS ON NIPT (PAPER V) 
4.7.1 Awareness, interest and information preferences regarding NIPT 
Attitudes towards NIPT were studied among 1,003 women prior to the introduction of the 
method into Swedish healthcare. Although 60% of the women stated that they had heard 
about the method previously, 74% stated that they would like to use the method if available. 
This implies that a test with the characteristics of NIPT; i.e. both highly accurate and safe for 
the fetus, is very desirable by the pregnant population. Among the remaining women, 12% 
stated that they would not like to use the method, whereas 14% were not sure. Internationally, 
the interest in using NIPT has been shown to vary greatly between different countries, 
ranging from 51% in the Netherlands to 88% in the UK111-113. Based on that 64% of the 
women in Stockholm took FCT in 2014, the proportion of women accepting prenatal 
screening would potentially increase by at least 10% if FCT was substituted by NIPT. As of 
today, NIPT is only offered women classified as high risk by FCT, i.e. a risk exceeding 
1:200.  
Although most of the women seemed to have decided whether they wanted to use NIPT or 
not, a large majority stated that they would need information to facilitate their decision if to 
undergo the test. However, the proportion differed significantly between women who had 
stated that they wanted to use the test and the women who would not use it; 84% vs. 64%, 
respectively (p<0.001). This might indicate that women who are against chromosomal testing 
are more convinced about their choice. The most requested way to receive information was 
orally by the midwife (80%), followed by written information (49%), however often in 
combination. 
Regarding which information the women would like to get if they indeed would use the test, 
yet again the answers differed significantly between women potentially willing to use NIPT 
and women who would not use the test. Out of the women potentially willing to use NIPT, 
96% would like to know if the fetus had Down syndrome, whereas the corresponding 
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proportion among women not willing to use the test was only 48% (p<0.001). However, 
considerably more (69%) would like to know if the fetus had another, more severe 
chromosomal abnormality (Figure 8). Out of the women who would potentially use NIPT, 
78% stated that they would be willing to pay by themselves if the cost would not be covered 
by the national health insurance. Most of them (74%) would pay approximately €50 to €100, 
whereas approximately 10% stated that they would pay €500 or more.  
 
Figure 8. Desired information from a NIPT analysis. *** = p<0.001 
4.7.2 Attitudes towards prenatal examinations in general 
The overwhelming majority, 91%, considered examinations aiming to detect fetal 
abnormalities to be good. However, 27% perceived such examinations as frightening. Yet, 
the majority thought that the examinations are calming (69%), and that it is self-evident to 
undergo fetal examinations (56%). The frequencies of all answers are displayed in Figure 9. 
 
Figure 9. Pregnant women’s attitudes towards prenatal examinations. 
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When asked about attitudes towards specific prenatal examination methods, as many 97% 
were positive towards ultrasound. This can probably be explained by that ultrasound is 
appreciated also by women who do not want to perform chromosomal screening on their 
fetuses, as well as that the visualization itself is an often perceived as an emotional experience 
that facilitates attachment114. Conversely, only 42% of the women were positive towards 
invasive testing. The positive attitudes towards NIPT and FCT were approximately similar; 
73% vs. 78%, respectively.  
4.7.3 Attitudes towards chromosomal abnormalities and risk perception 
Almost one third of the women in the cohort (n=306, 31%) stated that it would not matter if 
their baby was born with a chromosomal abnormality such as Down syndrome, whereas 45% 
(n=450) stated that they would react negatively, and 18% (n=180) would find it very 
negative. The proportions did not differ between women who had previous children or not 
(p=0.777), or between women who had experienced miscarriages or not (p=0.382). However, 
women willing to use NIPT stated that they would react negatively or very negatively to a 
significantly higher extent than women who would not like to do the test (77% vs. 36%, 
p<0.001). 
When the women were asked about their self-perceived probability of having a child with a 
chromosomal abnormality, 73% thought it was unlikely, 4% thought it was likely, and 21% 
stated that they did not know. The results did not differ between women below or above 35 
years of age (p=0.618). The women were asked to specify what they thought was a high 
probability, by selecting an alternative on a scale ranging from 1:1 to 1:20,000. The most 
frequent answer, selected by 33% (n=224) was 1:200, i.e. the threshold used as high risk in 
FCT screening in Sweden. However, almost one third (n=301, 30%) answered “I don’t 
know”. When the women were asked to specify what they thought was their own probability 
of having a child with a chromosomal abnormality, as many as 58% (n=241) answered “I 
don’t know”. The answers could indicate that they either did not know, or that they did not 
know how to interpret the values. The challenge of communicating risk information in a 
comprehensible fashion has been addressed previously115, and additionally, risk perception 
varies depending on factors such as personal background, gender and socio-economic status, 
and is highly influenced by emotions and affect116,117. Out of the 171 women giving an 
answer, 95% thought that their probability was 1:5,000 or less. This could be put in relation 
to the overall age associated risk, which at 32 years (i.e. the mean age of the participants in 
the study) is 1:769 for trisomy 21, and 1:323 for any chromosomal abnormality46. 
4.7.4 Decision making regarding prenatal chromosomal examinations 
Almost all women (96%) stated that the decision to undergo prenatal chromosomal 
examinations is their own. However, the majority stated that they make the decision together 
with their partner (68%). Only 14% and 10% stated that they were affected by the midwife or 
doctor at the maternity clinic, respectively. Hopefully, this reflects that expectant parents feel 
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sufficiently informed to make their own choice, and that the health professionals have 
managed to deliver information about the examinations in an objective manner. 
The main factor affecting the women’s decision if to undergo fetal chromosome screening 
was worry about the baby’s health (83%), followed by the desire to have as much information 
as possible about the fetus (55%). Only 3% stated that they were affected by expectations 
from others, and even fewer (1%) by the feeling that “everyone else is having such tests”. Out 
of the women who did not want to use NIPT, 20% stated that nothing influenced their 
decision as they were already convinced that they did not want to do such tests, and another 
38% did not choose any of the given alternatives, which further strengthens the hypothesis 
that the women who not want to perform prenatal chromosomal examinations are more 
convinced about their choice.  
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5 CONCLUDING REMARKS 
The studies included in this thesis have focused on the development and evaluation of new 
procedures to diagnose genetic disorders in fetal life, and thereby improve prenatal care and 
increase our knowledge of the normal and abnormal fetal development, as well as 
investigation of pregnant women’s attitudes towards prenatal diagnosis. The following 
conclusions can be drawn from the studies: 
 In the analysis of stillbirth, conventional chromosome analysis is prone to failure, and 
QF-PCR is a useful complementary method. Analysis with CMA has a higher success 
rate as well as a higher aberration detection frequency than both karyotyping and QF-
PCR, and therefore we conclude that CMA is a valuable tool for identification of 
chromosomal aberrations in stillbirth.  
 Our results from analysis of 290 stillbirth cases give further support to the hypothesis 
that cardiac channelopathies might contribute to stillbirth. Furthermore, our results 
suggest an increased frequency of pathogenic SNVs in genes associated with 
cardiomyopathies and CHD in stillbirth compared with the general population. 
Screening for pathogenic SNVs in genes associated with heart disease might be 
valuable in cases of stillbirth where today’s conventional investigation does not reveal 
the underlying cause of fetal demise.  
 We showed that fetal tissue calcifications are highly associated with chromosomal 
abnormalities, especially in combination with congenital malformations. 
Identification of a calcification together with a malformation at autopsy more than 
doubles the probability of detecting a chromosomal abnormality, compared with 
identification of a malformation only. We propose that identification of a fetal tissue 
calcification at autopsy, and potentially also at ultrasound examination, should infer 
special attention towards co-existence of malformations, as this would be a strong 
indicator for a chromosomal abnormality. 
 We concluded that the evaluated amplification-free sequencing protocol can 
potentially be used for NIPT, as we have shown that it can distinguish trisomies from 
healthy controls in clinical samples. Compared with other NIPT protocols, the 
amplification-free method can be used on smaller quantities of input DNA, reduces 
GC bias and increases genome coverage. The amplification-free method would be the 
method of choice when coverage is important, when partially degraded input material 
is used, or when there is a need of low amplification-bias combined with low cost and 
scarce material.  
 Regarding attitudes towards prenatal examinations, the overwhelming majority of a 
cohort of 1,003 pregnant women considered analyses aiming to detect fetal 
abnormalities to be good. Additionally, the majority had a positive attitude towards 
NIPT and would like to use the test if available. The main factor affecting the 
women’s decision to undergo prenatal chromosome examinations was worry about 
the baby’s health. 
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6 FUTURE PERSPECTIVES 
The results from the studies included in this thesis have provided support for the value of 
using various genetic analysis methods in the field of prenatal diagnosis, as well as insights to 
the prevalence of genetic aberrations in fetuses. In clinical practice, the results have led to 
fetuses with tissue calcifications being routinely analyzed by chromosome analysis. There are 
also ongoing discussions regarding whether to analyze all cases of stillbirth with CMA, 
although it has not yet been implemented.  
Medical genetics is an expansive field, and the methods are rapidly shifting towards high-
throughput, genome wide analyses. The development of high-resolution chromosome 
analysis methods, such as CMA, has without a doubt led to a massive increase in our 
knowledge about submicroscopic chromosomal abnormalities, and to identification of 
numerous syndromes. However, these techniques are already on the verge of becoming 
outdated, and instead replaced by sequencing technologies.  Because of the increasing quality 
of sequencing data, together with the rapid decrease in sequencing cost, it is likely that a great 
proportion of genetic analyses will be substituted by whole genome sequencing (WGS) 
within the upcoming years. 
In addition to the sequence analysis in itself, WGS can successfully be used to identify 
CNVs118, and has been shown to enable detection of mosaicism down to a level of ~2%119. 
However, with more data come more incidental findings, which is an even bigger issue when 
it comes to prenatal testing. For example, how should we handle the incidental finding of a 
late-onset lethal disorder? Although lethal today, there might be a treatment by the time that 
the fetus has become an adult person at risk of disease development. Clear and carefully 
prepared guidelines regarding how to handle these types of situations are needed. A way to 
avoid these types of dilemmas is simply to not analyze the complete genome. A good 
compromise could be the use of gene panels, but instead of sequencing panels, like the one 
used in Paper II, WGS is performed and an in silico panel is applied to the sequence data. As 
our knowledge about disease associated genes increases, the already available sequencing 
data can be reanalyzed in concerned cases. Analysis of the complete genome should only be 
performed in a clinical setting if there is a clear phenotype and segregation analysis is 
possible.  
As mentioned in the “Ethical considerations” section, there are concerns regarding the 
“slippery slope effect” in genetic analysis, i.e. that the spectrum of traits tested for will widen 
to an extent where even non-medical indications will be included. Simultaneously, the 
majority of pregnant women participating in Paper V claimed that one of the factors 
affecting their decision to undergo chromosome screenings is their desire to have as much 
information as possible about their fetuses. The healthcare community has a responsibility to 
set boundaries for what is actually healthcare, to avoid shaping a society where we screen for 
imperfections.   
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Although we have come quite far in our capability to elucidate the function of protein-coding 
genes to interpret genetic aberrations, there is a huge gap in our knowledge when moving to 
oligo- or polygenic disorders. Also, we have only started to understand the regulatory 
components of the genome, or the functions of e.g. long non-coding RNA genes. In order to 
take the next big leap towards delineating the functions of the genome, we have to move from 
regarding it as a linear structure, i.e. solely a sequence of base pairs, to the complex three 
dimensional structure from which it actually performs its actions in the cell nucleus.  
6.1 PERSONAL REFLECTION 
When I started my studies in biomedicine near a decade ago, we were taught that 90% of the 
human genome consists of junk-DNA. As our knowledge deepens, this idea seems more and 
more naïve – why would something be junk only because we don’t understand it? My 
personal experience has taught me that the more I learn, the more I realize how much we 
have yet to understand; a realization that can be frustrating, but that also makes you humble 
towards the intricate machinery that constitutes life, created by millions of years of evolution. 
Although we may never know every detail about the genome, I believe that our continuous 
discoveries will have a positive impact on our lives, by a better understanding of disease 
mechanisms and improvement of care.  
 
 
 
September, 2016 
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7 SAMMANFATTNING PÅ SVENSKA 
Med hjälp av fosterdiagnostik har vi möjlighet att upptäcka svåra sjukdomar redan hos foster. 
Att fastställa en diagnos är viktigt för omhändertagande av både fostret och de blivande 
föräldrarna, och vid förekomst av en genetisk sjukdom ger en fastställd diagnos dessutom 
möjlighet att beräkna återupprepningsrisken i eventuella efterföljande graviditeter. Kännedom 
om det sjukdomsorsakande anlaget har också betydelse för övrig släkt, då det kan förekomma 
ytterligare anlagsbärare med ökad risk att få sjuka barn. Under senare år har det skett en 
dramatisk utveckling av metoder som används inom det genetiska fältet. Med dessa metoder 
kan vi analysera stora mängder genetisk information, i en upplösning som tidigare inte varit 
möjlig. I detta projekt har ett flertal av dessa nya metoder använts och utvärderats, i syfte att 
förbättra fosterdiagnostiken och öka vår kunskap om fosters utveckling i både hälsa och 
sjukdom. Dessutom har vi undersökt gravida kvinnors attityder, medvetenhet och preferenser 
gällande fosterdiagnostik. 
I delstudie 1 studerades intrauterin fosterdöd (IUFD), vilket definieras som fosterdöd som 
inträffar från och med 22 fullgångna graviditetsveckor. Förekomsten av IUFD i Sverige har i 
princip legat konstant kring 3-4 per 1000 levande födda barn sedan 1980-talet, och trots att 
samtliga fall genomgår en omfattande undersökning, som innefattar fysisk bedömning/ 
obduktion, infektionstestning och kromosomanalys, förblir den bakomliggande orsaken till 
att fostren dött i många fall oförklarad. Den typ av kromosomanalys som traditionellt använts 
för att analysera fosterceller har använts i flera decennier, och är behäftad med vissa 
nackdelar. Dels har metoden en låg upplösning, vilket innebär att en eventuell 
kromosomavvikelse måste vara väldigt stor för att den över huvud taget ska kunna upptäckas, 
och dels kräver metoden cellodling, vilket är en känslig process som har en benägenhet att 
misslyckas – särskilt i samband med fosterdöd, då fostrets vävnader i många fall börjat 
upplösas, och cellerna således är i för dåligt skick för att kunna odlas över huvud taget. I fall 
där kromosomanalysen misslyckats har man under senare år kunnat utföra en alternativ 
undersökning med hjälp av en metod kallad QF-PCR (quantitative fluorescence polymerase 
chain reaction). Med denna analys kan man upptäcka aneuploidier, det vill säga förekomst av 
för många eller för få kromosomkopior, av ett fåtal utvalda kromosomer. Metoden har som 
fördel att den inte kräver cellodling, medan nackdelen är att analysen ger mycket mindre 
information jämfört med vanlig kromosomanalys. Under de senaste åren har nya typer av 
analyser utvecklats, till exempel kromosomal mikroarray (CMA). Detta är en typ av 
högupplöst kromosomanalys, där man genom att jämföra sitt patient-DNA med ett kontroll-
DNA kan identifiera tillkomst eller bortfall av genetiskt material hos patienten. I denna studie 
analyserade vi 90 fall av IUFD utan en känd genetisk diagnos med CMA, för att undersöka 
metodens fördelar i IUFD-utredningar. Dessutom sammanställdes resultat från traditionell 
kromosomanalys från samtliga IUFD-fall som inträffat i Stockholms län under en 
femårsperiod; 2008-2012. 
I sammanställningen av kliniska resultat fann vi att 7.5% av IUFD-fallen hade 
kromosomavvikelser som identifierats med traditionell kromosomanalys eller QF-PCR. Med 
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hjälp av CMA kunde vi identifiera ytterligare två kända syndrom, en avvikelse med direkt 
påverkan på en känd sjukdomsorsakande gen, samt 26 avvikelser av oklar klinisk signifikans. 
Dessutom gav CMA lyckade analysresultat av hög kvalitet i samtliga analyserade fall, till 
skillnad från traditionell kromosomanalys som misslyckades i var femte fall. Vi drog därför 
slutsatsen att CMA är ett värdefullt redskap i analysen av IUFD, då metoden ökade både 
andelen diagnoser och andelen lyckade analyser. 
Även i delstudie 2 inriktade vi oss på IUFD. Under senare år har rapporter publicerats som 
indikerar att olika typer av hjärtsjukdomar, främst störningar i hjärtats rytm, kan orsaka 
fosterdöd. Med hjälp av dagens sekvenseringsteknik, så kallad massiv parallellsekvensering, 
har vi möjlighet att sekvensera en stor mängd genetiskt material på ett sätt som fram till 
nyligen inte varit möjligt utan en enorm arbetsbelastning. I denna studie analyserade vi 290 
fall utan en känd genetisk diagnos med en genpanel, inriktad mot 79 gener associerade med 
hjärtsjukdomar och hjärtats utveckling. 
Vi fann att 62 (21%) av fallen hade 1-2 genetiska varianter som fanns beskrivna som 
sjukdomsorsakande. Majoriteten var kopplade till olika typer av rytmrubbningar, medan en 
andel var kopplade till påverkan på hjärtmuskulaturen eller associerade med olika former av 
missbildningar. Vi jämförde våra fynd med sekvenseringsdata från över 60,000 vuxna 
individer (tillgängligt från The Exome Aggregation Consortium, ExAC) och såg att de 
specifika genetiska varianterna var signifikant överrepresenterade bland IUFD-fallen, vilket 
gav ökat stöd till att de skulle kunna vara associerade med fosterdöd. Ytterligare studier är 
nödvändiga för att stärka sambandet mellan IUFD och hjärtsjukdom, men våra resultat 
indikerar att denna typ av analys skulle kunna vara värdefull i fall där den vanliga 
undersökningen inte identifierar den bakomliggande orsaken till fosterdöd. 
I delstudie 3 studerade vi foster med vävnadsförkalkningar. Denna typ av förkalkningar 
upptäcks ibland i samband med obduktion, men även, dock mer sällan, under 
ultraljudsundersökningar. Även om man under lång tid känt till förekomsten av förkalkningar 
har deras biologiska relevans inte blivit undersökt i någon större utsträckning. Spridda 
rapporter har indikerat en association mellan förkalkningar och infektion, 
cirkulationsrubbningar, missbildningar eller kromosomavvikelser. För att identifiera faktorer 
kopplade till förkalkningar har vi utfört en fall-kontrollstudie, innefattande 151 foster med 
vävnadsförkalkningar, vilket är den största grupp i sitt slag som hittills beskrivits. För varje 
fall identifierade vi två kontrollfoster, som var matchade mot fallen i avseende på 
graviditetsvecka och typ av död, det vill säga missfall, fördröjt missfall (så kallat missed 
abortion), inducerat avbrytande eller IUFD. Traditionell kromosomanalys hade tidigare 
utförts inom kliniken på 290 av de sammanlagt 453 fostren. De resterande 163 fallen blev 
analyserade med QF-PCR inom ramen för detta projekt. 
Förkalkningarna var främst lokaliserade i lever, men även i hjärta, tarmar och andra 
vävnader. Vi fann att foster med vävnadsförkalkningar hade kromosomavvikelser i en 
signifikant högre grad än kontroller; 50% jämfört med 20%. De vanligast förekommande 
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kromosomavvikelserna inkluderade trisomi 21 (Downs syndrom), trisomi 18 (Edwards 
syndrom) och monosomi X (Turners syndrom). När vi jämförde fall och kontroller med 
kromosomavvikelser fann vi dessutom att fallen hade en signifikant högre andel 
missbildningar än kontrollerna. Vi fann däremot inget stöd för en association mellan 
förkalkningar och infektion. Vi drog således slutsatsen att förekomst av vävnadsförkalkningar 
hos foster är associerade med en hög risk för kromosomavvikelser, särskilt i kombination 
med missbildningar, och föreslår att man vid upptäckt av en förkalkning riktar särskild 
uppmärksamhet mot förekomst av missbildningar då det i dessa fall är hög sannolikhet att en 
kromosomavvikelse föreligger. Resultaten från denna studie har lett till att foster med 
förkalkningar numera rutinmässigt undersöks med kromosomanalys. 
Att identifiera kromosomavvikelser hos foster under pågående graviditet har traditionellt 
gjorts med hjälp av ett invasivt test, det vill säga fostervatten- eller moderkaksprov. Dessa 
metoder att få tillgång till fosterceller har använts i över 40 år och är förenade med en risk för 
missfall i upp till 0.5% av ingreppen. Fosterdiagnostikfältet håller dock på att genomgå en 
omfattande förändring på grund av att icke-invasiv fosterdiagnostik, så kallad NIPT (non-
invasive prenatal testing) håller på att etablera sig internationellt.  
Under en pågående graviditet sker en stor omsättning av celler i främst placentan. Detta leder 
till att korta bitar av fostrets DNA läcker ut i moderns blodomlopp, och att man därmed kan 
få tillgång till fostrets arvsmassa genom ett enkelt blodprov. Med hjälp av massiv 
parallellsekvensering av detta så kallade cellfria foster-DNA (cffDNA) möjliggörs 
identifiering av kromosomavvikelser. Ett problem med dagens metoder för NIPT är att de 
innehåller ett amplifieringssteg, vilket innebär att man med hjälp av en enzymatisk reaktion 
mångdubblar mängden DNA som sedan ska sekvenseras. Amplifiering leder dock 
oundvikligen till ett systematiskt fel (”bias”) på grund av att vissa DNA-sekvenser 
amplifieras mer effektivt än andra. Om man kunde ta bort amplifieringssteget skulle 
säkerheten i resultaten från NIPT potentiellt kunna öka. I delstudie 4 har vi utvärderat ett 
amplifieringsfritt NIPT-protokoll, i syfte att klarlägga metodens möjlighet att korrekt 
identifiera aneuploidier hos foster.  
Metoden testades på 31 prover från gravida kvinnor, av vilka 15 bar foster med verifierade 
kromosomavvikelser. Samtliga 15 fall blev korrekt klassificerade som avvikande, men i ett 
fall där fostret bar två kromosomavvikelser; trisomi 18 och XXY, misslyckades metoden att 
identifiera den extra X-kromosomen. För att få klarhet i varför X-kromosomen inte 
identifierades gjordes uppföljande analyser med QF-PCR och CMA. Dessa visade att fostret i 
själva verket var mosaiker och att den extra X-kromosomen endast fanns i en andel av 
cellerna, medan resterande celler hade normal könskromosomuppsättning. Trisomi 18 
förekom dock i samtliga celler. Denna mosaicism förklarar troligen att den extra X-
kromosomen inte upptäcktes i NIPT-analysen. Vi drog slutsatsen att den amplifieringsfria 
NIPT-metoden potentiellt kan användas för att upptäcka kromosomavvikelser hos foster, då 
den visades kunna identifiera avvikelser i kliniska prover. I jämförelse med andra NIPT-
38 
 
protokoll kan det användas på mindre mängder DNA, samtidigt som det minskar bias och 
ökar täckningsgraden.  
NIPT implementerades som klinisk analys på Klinisk Genetik, Karolinska 
Universitetssjukhuset, i juni 2015. I samband med införandet av nya metoder är det av värde 
att studera hur metoden kan komma att tas emot av de potentiella användarna; i detta fall 
gravida kvinnor. I delstudie 5 har 1003 gravida kvinnor rekryterats i väntrummen till nio 
mödravårdscentraler lokaliserade i olika delar av Stockholmsområdet, utvalda för att ge en 
bred representation i socioekonomisk status bland deltagarna. Kvinnorna fick fylla i en enkät 
i syfte att undersöka deras inställning till NIPT och huruvida de hade kännedom om metoden. 
Vi undersökte dessutom kvinnornas inställning till fosterdiagnostik i stort, hur deras beslut 
gällande att genomgå denna typ av undersökningar fattas, liksom hur information om dessa 
undersökningar ska ges på bästa sätt. Dessutom studerades inställningen till att få ett barn 
med en kromosomavvikelse, samt kvinnornas egen uppfattning om sannolikheten för att det 
ska ske.  
Vi fann att 60% av kvinnorna hade hört talas om NIPT tidigare, men ändå uppgav 74% att de 
var säkra på att de skulle vilja genomgå testet om det fanns tillgängligt. Det tyder på att ett 
test med de egenskaper som återfinns hos NIPT är efterlängtat av den gravida populationen. 
Utöver ett intresse för NIPT uppgav hela 91% av kvinnorna att de var positivt inställda till 
fosterundersökningar över lag. Den främsta faktorn som påverkar kvinnornas beslut att 
genomgå kromosomundersökningar var oro för barnets hälsa (83%) följt av en önskan att 
vilja ha så mycket information som möjligt om fostret (55%). Majoriteten av deltagarna 
uppgav att de föredrar att få muntlig information om fosterundersökningar av barnmorskan på 
mödravårdscentralen. En tredjedel av kvinnorna uppgav att det inte hade någon betydelse ifall 
deras barn skulle visa sig ha en kromosomavvikelse som till exempel Downs syndrom, 
samtidigt som en stor majoritet uppskattade att sannolikheten att det skulle inträffa som 
mycket låg. 
Resultaten från studierna i denna avhandling ger ökad insikt om hur olika genetiska metoder 
kan användas inom fosterdiagnostik. Därutöver har vi ökat vår kunskap om olika typer av 
genetiska avvikelser hos foster.  
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